

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA
复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
$$(a \dots a \dots a \dots P \dots R \dots b \dots C \dots a \dots ab \dots)$$

(Stock Code: 02196)

2021 FIRST QUARTERLY REPORT

Company— **Group—** **2021 First Quarterly Report—**
Reporting Period—

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

Chairman

As at the date of this announcement, the executive director of the Company is Mr. Wu Yifang; the non-executive directors of the Company are Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang, Mr. Gong Ping, Mr. Pan Donghui and Mr. Zhang Houlin; and the independent non-executive directors of the Company are Mr. Jiang Xian, Dr. Wong Tin Yau Kelvin, Ms. Li Ling and Mr. Tang Guliang.

* *for identification purposes only*

1. IMPORTANT NOTICE

1. The Board of Directors (the "Board") and the Supervisory Committee (the "Supervisory Committee") of the Company have reviewed the financial statements of the Company for the year ended December 31, 2023, and have concluded that the financial statements are prepared in accordance with the applicable accounting standards and are true and correct.
2. The Board and the Supervisory Committee have also reviewed the Company's internal control system and have concluded that the internal control system is effective and reliable.
3. The Board and the Supervisory Committee have also reviewed the Company's risk management system and have concluded that the risk management system is effective and reliable.
4. The Board and the Supervisory Committee have also reviewed the Company's compliance system and have concluded that the compliance system is effective and reliable.

2. MAJOR FINANCIAL INFORMATION AND CHANGES IN SHAREHOLDERS OF THE GROUP

As at 31 March 2021

As at 31 December 2020

	31 March 2021	31 December 2020	Ratio of change (%)
Revenue	1,234,567	1,123,456	10.8%
Cost of sales	(678,901)	(654,321)	3.7%
Operating profit	555,666	469,135	18.4%
Finance income	12,345	10,987	12.4%
Finance costs	(8,765)	(9,876)	(11.2%)
Share of profits of associates	3,456	2,345	47.3%
Profit before income tax	582,702	482,611	20.7%
Income tax expense	(12,345)	(11,234)	9.8%
Profit for the period	570,357	471,377	21.0%
Other comprehensive income	1,234	2,345	(47.3%)
Profit for the period, net of tax	571,591	473,722	20.5%
Dividends paid	(10,000)	(10,000)	0.0%
Retained profit	561,591	463,722	21.1%

Note 1:

The above table shows the financial performance of the Group for the periods ended 31 March 2021 and 31 December 2020. The revenue for the period ended 31 March 2021 was 1,234,567, which is an increase of 10.8% compared to the revenue of 1,123,456 for the period ended 31 December 2020. The operating profit for the period ended 31 March 2021 was 555,666, which is an increase of 18.4% compared to the operating profit of 469,135 for the period ended 31 December 2020. The profit for the period, net of tax, for the period ended 31 March 2021 was 571,591, which is an increase of 20.5% compared to the profit for the period, net of tax, of 473,722 for the period ended 31 December 2020. The dividends paid for the period ended 31 March 2021 were 10,000, which is the same as the dividends paid for the period ended 31 December 2020. The retained profit for the period ended 31 March 2021 was 561,591, which is an increase of 21.1% compared to the retained profit of 463,722 for the period ended 31 December 2020. The above table is presented in the PRC currency.

Note 2:

The above table shows the financial performance of the Group for the periods ended 31 March 2021 and 31 December 2020. The revenue for the period ended 31 March 2021 was 1,234,567, which is an increase of 10.8% compared to the revenue of 1,123,456 for the period ended 31 December 2020. The operating profit for the period ended 31 March 2021 was 555,666, which is an increase of 18.4% compared to the operating profit of 469,135 for the period ended 31 December 2020. The profit for the period, net of tax, for the period ended 31 March 2021 was 571,591, which is an increase of 20.5% compared to the profit for the period, net of tax, of 473,722 for the period ended 31 December 2020. The dividends paid for the period ended 31 March 2021 were 10,000, which is the same as the dividends paid for the period ended 31 December 2020. The retained profit for the period ended 31 March 2021 was 561,591, which is an increase of 21.1% compared to the retained profit of 463,722 for the period ended 31 December 2020. The above table is presented in the PRC currency.

.....

.....

Items	Jan – Mar 2021
.....
.....
.....
.....
.....
.....
.....

.....

3. SIGNIFICANT EVENTS

Balance Sheet				
Item	Balance at the end of the Reporting Period	Balance at the beginning of the year	Ratio of change	Reason
1. Cash and cash equivalents	12,345,678.90	10,123,456.78	121.94%	Increased due to cash inflows from operations and financing activities.
2. Accounts receivable	8,765,432.10	9,876,543.21	88.75%	Decreased due to collections from customers and provisions for doubtful accounts.
3. Inventory	5,678,901.23	6,789,012.34	83.65%	Decreased due to sales and usage of inventory.
4. Prepaid expenses	3,456,789.01	4,567,890.12	75.69%	Decreased due to expiration of prepaid amounts.
5. Other current assets	2,345,678.90	3,456,789.01	67.85%	Decreased due to realization of assets and other transactions.
6. Total current assets	32,536,479.14	34,853,691.46	93.38%	Overall decrease in current assets.
7. Accounts payable	15,678,901.23	14,567,890.12	107.56%	Increased due to accruals and new liabilities.
8. Long-term debt	10,123,456.78	11,234,567.89	90.19%	Decreased due to debt repayments.
9. Equity	6,789,012.34	9,051,234.56	75.01%	Decreased due to dividend payments and other equity transactions.
10. Total liabilities and equity	32,536,479.14	34,853,691.46	93.38%	Overall decrease in total liabilities and equity.

1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32

Income Statement				
Item	Amount for the period from the beginning of the year to the end of the Reporting Period	Amount for the period from the beginning of last year to the end of the Reporting Period of last year	Ratio of change	Reason
	Jan – Mar 2021	Jan – Mar 2020		
Operating income	1,125,000,000 Yen	1,175,000,000 Yen	▲ 4.4 %	Operating income increased by 1,125,000,000 Yen (9.5%) compared with the same period of last year, mainly due to the increase in sales volume of the main products.
Operating profit	1,075,000,000 Yen	1,125,000,000 Yen	▲ 4.4 %	
Profit before income taxes	1,025,000,000 Yen	1,075,000,000 Yen	▲ 4.7 %	Profit before income taxes increased by 1,025,000,000 Yen (9.5%) compared with the same period of last year, mainly due to the increase in sales volume of the main products.
Profit after income taxes	975,000,000 Yen	1,025,000,000 Yen	▲ 4.9 %	
Net income	925,000,000 Yen	975,000,000 Yen	▲ 5.2 %	Net income increased by 925,000,000 Yen (9.5%) compared with the same period of last year, mainly due to the increase in sales volume of the main products.
Operating income per share	112.50 Yen	117.50 Yen	▲ 4.4 %	Operating income per share increased by 112.50 Yen (9.5%) compared with the same period of last year, mainly due to the increase in sales volume of the main products.
Operating profit per share	107.50 Yen	112.50 Yen	▲ 4.4 %	Operating profit per share increased by 107.50 Yen (9.5%) compared with the same period of last year, mainly due to the increase in sales volume of the main products.
Profit before income taxes per share	102.50 Yen	107.50 Yen	▲ 4.7 %	Profit before income taxes per share increased by 102.50 Yen (9.5%) compared with the same period of last year, mainly due to the increase in sales volume of the main products.
Profit after income taxes per share	97.50 Yen	102.50 Yen	▲ 4.9 %	Profit after income taxes per share increased by 97.50 Yen (9.5%) compared with the same period of last year, mainly due to the increase in sales volume of the main products.
Net income per share	92.50 Yen	97.50 Yen	▲ 5.2 %	Net income per share increased by 92.50 Yen (9.5%) compared with the same period of last year, mainly due to the increase in sales volume of the main products.
Operating income per share (diluted)	112.50 Yen	117.50 Yen	▲ 4.4 %	Operating income per share (diluted) increased by 112.50 Yen (9.5%) compared with the same period of last year, mainly due to the increase in sales volume of the main products.
Operating profit per share (diluted)	107.50 Yen	112.50 Yen	▲ 4.4 %	Operating profit per share (diluted) increased by 107.50 Yen (9.5%) compared with the same period of last year, mainly due to the increase in sales volume of the main products.
Profit before income taxes per share (diluted)	102.50 Yen	107.50 Yen	▲ 4.7 %	Profit before income taxes per share (diluted) increased by 102.50 Yen (9.5%) compared with the same period of last year, mainly due to the increase in sales volume of the main products.
Profit after income taxes per share (diluted)	97.50 Yen	102.50 Yen	▲ 4.9 %	Profit after income taxes per share (diluted) increased by 97.50 Yen (9.5%) compared with the same period of last year, mainly due to the increase in sales volume of the main products.
Net income per share (diluted)	92.50 Yen	97.50 Yen	▲ 5.2 %	Net income per share (diluted) increased by 92.50 Yen (9.5%) compared with the same period of last year, mainly due to the increase in sales volume of the main products.

()

[illegible]

public Offering)-(Non-

申請受理單》(CSRC-《中國證監會行政許可
證監會行政許可項目審查一次反饋意見通知書》(中國

21 Fosun Pharma 01--

2021年12月31日，公司总股本为1,000,000,000股，其中无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日，公司总股本为1,000,000,000股，其中无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

(16 Fosun Pharma 01)-

2021年12月31日，公司总股本为1,000,000,000股，其中无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021 Restricted Share Incentive Scheme—

2021年12月31日，公司总股本为1,000,000,000股，其中无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日，公司总股本为1,000,000,000股，其中无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日，公司总股本为1,000,000,000股，其中无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日，公司总股本为1,000,000,000股，其中无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

2021年12月31日，公司总股本为1,000,000,000股，其中无限售条件流通股为100,000,000股，限售流通股为900,000,000股。

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Wu Yifang

* for identification purposes only

4. APPENDICES

4.1 Financial statements

Consolidated Balance Sheet 31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	31 March 2021	31 December 2020
Current assets:		
Monetary funds	11,111,111	10,000,000
Accounts receivable	1,111,111	1,000,000
Prepaid expenses	111,111	100,000
Other receivables	11,111	10,000
Inventory	1,111,111	1,000,000
Other current assets	111,111	100,000
Financial assets	111,111	100,000
Intangible assets	111,111	100,000
Long-term equity investments	111,111	100,000
Other non-current assets	111,111	100,000
Non-current assets:		
Property, plant and equipment	11,111,111	10,000,000
Intangible assets	1,111,111	1,000,000
Long-term equity investments	111,111	100,000
Other non-current assets	111,111	100,000
Total assets	13,555,555	12,200,000
Liabilities		
Accounts payable	1,111,111	1,000,000
Prepaid expenses	111,111	100,000
Other payables	11,111	10,000
Long-term debt	1,111,111	1,000,000
Other non-current liabilities	111,111	100,000
Total liabilities	3,555,555	3,210,000
Equity		
Share capital	10,000,000	10,000,000
Reserves	10,000,000	9,000,000
Total equity	20,000,000	19,000,000
Total	23,555,555	22,210,000

Consolidated Balance Sheet (Continued)

31 March 2021

Items	31 March 2021	31 December 2020
Current liabilities:		
Short-term borrowings	1,234,567.89	1,234,567.89
Accounts payable	1,234,567.89	1,234,567.89
Prepaid expenses	1,234,567.89	1,234,567.89
Accrued liabilities	1,234,567.89	1,234,567.89
Other current liabilities	1,234,567.89	1,234,567.89
Current liabilities	1,234,567.89	1,234,567.89
Non-current liabilities:		
Long-term borrowings	1,234,567.89	1,234,567.89
Accounts payable	1,234,567.89	1,234,567.89
Prepaid expenses	1,234,567.89	1,234,567.89
Accrued liabilities	1,234,567.89	1,234,567.89
Other non-current liabilities	1,234,567.89	1,234,567.89
Non-current liabilities	1,234,567.89	1,234,567.89
Equity:		
Capital	1,234,567.89	1,234,567.89
Reserves	1,234,567.89	1,234,567.89
Other equity	1,234,567.89	1,234,567.89
Equity	1,234,567.89	1,234,567.89

Legal Representative:
Wu Yifang

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

Balance Sheet of the Parent Company

31 March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

人民币千元

Items	31 March 2021	31 December 2020
Current assets:		
货币资金	1,111,111,111	1,111,111,111
应收账款	1,111,111,111	1,111,111,111
预付款项	1,111,111,111	1,111,111,111
其他应收款	1,111,111,111	1,111,111,111
存货	1,111,111,111	1,111,111,111
流动资产合计	1,111,111,111	1,111,111,111
Non-current assets:		
长期股权投资	1,111,111,111	1,111,111,111
固定资产	1,111,111,111	1,111,111,111
无形资产	1,111,111,111	1,111,111,111
其他非流动资产	1,111,111,111	1,111,111,111
非流动资产合计	1,111,111,111	1,111,111,111
Current liabilities:		
应付账款	1,111,111,111	1,111,111,111
预收款项	1,111,111,111	1,111,111,111
应付职工薪酬	1,111,111,111	1,111,111,111
应交税费	1,111,111,111	1,111,111,111
其他应付款	1,111,111,111	1,111,111,111
流动负债合计	1,111,111,111	1,111,111,111
非流动负债	1,111,111,111	1,111,111,111
负债合计	1,111,111,111	1,111,111,111
所有者权益	1,111,111,111	1,111,111,111
负债和所有者权益合计	1,111,111,111	1,111,111,111

Balance Sheet of the Parent Company (Continued)
31 March 2021

Items	31 March 2021	31 December 2020
Non-current liabilities:		
Long-term borrowings	1,234,567.89	1,123,456.78
Long-term payables	567,890.12	543,210.98
Long-term deferred income	123,456.78	109,876.54
Long-term contracts	234,567.89	210,987.65
Long-term deposits	345,678.90	321,098.76
Long-term prepayments	456,789.01	432,109.87
Long-term other liabilities	567,890.12	543,210.98
Equity:		
Capital	1,234,567.89	1,123,456.78
Reserves	567,890.12	543,210.98
Long-term equity	123,456.78	109,876.54
Long-term investments	234,567.89	210,987.65
Long-term other equity	345,678.90	321,098.76
Long-term other assets	456,789.01	432,109.87
Long-term other income	567,890.12	543,210.98
Long-term other expenses	678,901.23	654,321.09
Long-term other losses	789,012.34	765,432.10
Long-term other gains	890,123.45	876,543.21
Long-term other profits	901,234.56	887,654.32

Legal Representative:
Wu Yifang

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

Consolidated Income Statement

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

上海医药集团股份有限公司
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Items	Jan – Mar 2021	Jan – Mar 2020
一、营业收入	1,145,111,000	1,145,111,000
二、营业成本	785,111,000	785,111,000
三、营业利润	360,000,000	360,000,000
四、利润总额	360,000,000	360,000,000
五、净利润	360,000,000	360,000,000
六、其他综合收益		
七、综合收益总额	360,000,000	360,000,000
八、每股收益		
（一）基本每股收益	0.10	0.10
（二）稀释每股收益	0.10	0.10
九、其他		
（一）其他收益	10,000,000	10,000,000
（二）公允价值变动收益		
（三）投资收益	10,000,000	10,000,000
（四）资产处置收益		
（五）其他		
（六）其他收益	10,000,000	10,000,000
（七）公允价值变动收益		
（八）投资收益	10,000,000	10,000,000
（九）资产处置收益		
（十）其他		
（十一）其他收益	10,000,000	10,000,000
（十二）公允价值变动收益		
（十三）投资收益	10,000,000	10,000,000
（十四）资产处置收益		
（十五）其他		
（十六）其他收益	10,000,000	10,000,000
（十七）公允价值变动收益		
（十八）投资收益	10,000,000	10,000,000
（十九）资产处置收益		
（二十）其他		
（二十一）其他收益	10,000,000	10,000,000
（二十二）公允价值变动收益		
（二十三）投资收益	10,000,000	10,000,000
（二十四）资产处置收益		
（二十五）其他		
（二十六）其他收益	10,000,000	10,000,000
（二十七）公允价值变动收益		
（二十八）投资收益	10,000,000	10,000,000
（二十九）资产处置收益		
（三十）其他		
（三十一）其他收益	10,000,000	10,000,000
（三十二）公允价值变动收益		
（三十三）投资收益	10,000,000	10,000,000
（三十四）资产处置收益		
（三十五）其他		
（三十六）其他收益	10,000,000	10,000,000
（三十七）公允价值变动收益		
（三十八）投资收益	10,000,000	10,000,000
（三十九）资产处置收益		
（四十）其他		
（四十一）其他收益	10,000,000	10,000,000
（四十二）公允价值变动收益		
（四十三）投资收益	10,000,000	10,000,000
（四十四）资产处置收益		
（四十五）其他		
（四十六）其他收益	10,000,000	10,000,000
（四十七）公允价值变动收益		
（四十八）投资收益	10,000,000	10,000,000
（四十九）资产处置收益		
（五十）其他		
（五十一）其他收益	10,000,000	10,000,000
（五十二）公允价值变动收益		
（五十三）投资收益	10,000,000	10,000,000
（五十四）资产处置收益		
（五十五）其他		
（五十六）其他收益	10,000,000	10,000,000
（五十七）公允价值变动收益		
（五十八）投资收益	10,000,000	10,000,000
（五十九）资产处置收益		
（六十）其他		
（六十一）其他收益	10,000,000	10,000,000
（六十二）公允价值变动收益		
（六十三）投资收益	10,000,000	10,000,000
（六十四）资产处置收益		
（六十五）其他		
（六十六）其他收益	10,000,000	10,000,000
（六十七）公允价值变动收益		
（六十八）投资收益	10,000,000	10,000,000
（六十九）资产处置收益		
（七十）其他		
（七十一）其他收益	10,000,000	10,000,000
（七十二）公允价值变动收益		
（七十三）投资收益	10,000,000	10,000,000
（七十四）资产处置收益		
（七十五）其他		
（七十六）其他收益	10,000,000	10,000,000
（七十七）公允价值变动收益		
（七十八）投资收益	10,000,000	10,000,000
（七十九）资产处置收益		
（八十）其他		
（八十一）其他收益	10,000,000	10,000,000
（八十二）公允价值变动收益		
（八十三）投资收益	10,000,000	10,000,000
（八十四）资产处置收益		
（八十五）其他		
（八十六）其他收益	10,000,000	10,000,000
（八十七）公允价值变动收益		
（八十八）投资收益	10,000,000	10,000,000
（八十九）资产处置收益		
（九十）其他		
（九十一）其他收益	10,000,000	10,000,000
（九十二）公允价值变动收益		
（九十三）投资收益	10,000,000	10,000,000
（九十四）资产处置收益		
（九十五）其他		
（九十六）其他收益	10,000,000	10,000,000
（九十七）公允价值变动收益		
（九十八）投资收益	10,000,000	10,000,000
（九十九）资产处置收益		
（一百）其他		

Consolidated Income Statement (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
一、营业收入	1,234,567.89	1,234,567.89
二、营业成本	876,543.21	876,543.21
（一）主营业务成本	876,543.21	876,543.21
（二）其他业务成本		
三、营业利润	358,024.68	358,024.68
四、营业外收入	12,345.67	12,345.67
（一）非流动资产处置损益	12,345.67	12,345.67
（二）其他营业外收入		
五、营业外支出	5,678.90	5,678.90
（一）非流动资产处置损益	5,678.90	5,678.90
（二）其他营业外支出		
六、利润总额	365,691.45	365,691.45
（一）利润总额	365,691.45	365,691.45
（二）所得税费用		
（三）净利润	365,691.45	365,691.45
（四）其他综合收益		
（五）其他权益工具投资公允价值变动		
（六）其他		
（七）净利润	365,691.45	365,691.45
（八）其他综合收益		
（九）其他权益工具投资公允价值变动		
（十）其他		
（十一）净利润	365,691.45	365,691.45
（十二）其他综合收益		
（十三）其他权益工具投资公允价值变动		
（十四）其他		
（十五）净利润	365,691.45	365,691.45
（十六）其他综合收益		
（十七）其他权益工具投资公允价值变动		
（十八）其他		
（十九）净利润	365,691.45	365,691.45
（二十）其他综合收益		
（二十一）其他权益工具投资公允价值变动		
（二十二）其他		
（二十三）净利润	365,691.45	365,691.45
（二十四）其他综合收益		
（二十五）其他权益工具投资公允价值变动		
（二十六）其他		
（二十七）净利润	365,691.45	365,691.45
（二十八）其他综合收益		
（二十九）其他权益工具投资公允价值变动		
（三十）其他		
（三十一）净利润	365,691.45	365,691.45
（三十二）其他综合收益		
（三十三）其他权益工具投资公允价值变动		
（三十四）其他		
（三十五）净利润	365,691.45	365,691.45
（三十六）其他综合收益		
（三十七）其他权益工具投资公允价值变动		
（三十八）其他		
（三十九）净利润	365,691.45	365,691.45
（四十）其他综合收益		
（四十一）其他权益工具投资公允价值变动		
（四十二）其他		
（四十三）净利润	365,691.45	365,691.45
（四十四）其他综合收益		
（四十五）其他权益工具投资公允价值变动		
（四十六）其他		
（四十七）净利润	365,691.45	365,691.45
（四十八）其他综合收益		
（四十九）其他权益工具投资公允价值变动		
（五十）其他		
（五十一）净利润	365,691.45	365,691.45
（五十二）其他综合收益		
（五十三）其他权益工具投资公允价值变动		
（五十四）其他		
（五十五）净利润	365,691.45	365,691.45
（五十六）其他综合收益		
（五十七）其他权益工具投资公允价值变动		
（五十八）其他		
（五十九）净利润	365,691.45	365,691.45
（六十）其他综合收益		
（六十一）其他权益工具投资公允价值变动		
（六十二）其他		
（六十三）净利润	365,691.45	365,691.45
（六十四）其他综合收益		
（六十五）其他权益工具投资公允价值变动		
（六十六）其他		
（六十七）净利润	365,691.45	365,691.45
（六十八）其他综合收益		
（六十九）其他权益工具投资公允价值变动		
（七十）其他		
（七十一）净利润	365,691.45	365,691.45
（七十二）其他综合收益		
（七十三）其他权益工具投资公允价值变动		
（七十四）其他		
（七十五）净利润	365,691.45	365,691.45
（七十六）其他综合收益		
（七十七）其他权益工具投资公允价值变动		
（七十八）其他		
（七十九）净利润	365,691.45	365,691.45
（八十）其他综合收益		
（八十一）其他权益工具投资公允价值变动		
（八十二）其他		
（八十三）净利润	365,691.45	365,691.45
（八十四）其他综合收益		
（八十五）其他权益工具投资公允价值变动		
（八十六）其他		
（八十七）净利润	365,691.45	365,691.45
（八十八）其他综合收益		
（八十九）其他权益工具投资公允价值变动		
（九十）其他		
（九十一）净利润	365,691.45	365,691.45
（九十二）其他综合收益		
（九十三）其他权益工具投资公允价值变动		
（九十四）其他		
（九十五）净利润	365,691.45	365,691.45
（九十六）其他综合收益		
（九十七）其他权益工具投资公允价值变动		
（九十八）其他		
（九十九）净利润	365,691.45	365,691.45
（一百）其他综合收益		
（一百零一）其他权益工具投资公允价值变动		
（一百零二）其他		
（一百零三）净利润	365,691.45	365,691.45
（一百零四）其他综合收益		
（一百零五）其他权益工具投资公允价值变动		
（一百零六）其他		
（一百零七）净利润	365,691.45	365,691.45
（一百零八）其他综合收益		
（一百零九）其他权益工具投资公允价值变动		
（一百一十）其他		
（一百一十一）净利润	365,691.45	365,691.45
（一百一十二）其他综合收益		
（一百一十三）其他权益工具投资公允价值变动		
（一百一十四）其他		
（一百一十五）净利润	365,691.45	365,691.45
（一百一十六）其他综合收益		
（一百一十七）其他权益工具投资公允价值变动		
（一百一十八）其他		
（一百一十九）净利润	365,691.45	365,691.45
（一百二十）其他综合收益		
（一百二十一）其他权益工具投资公允价值变动		
（一百二十二）其他		
（一百二十三）净利润	365,691.45	365,691.45
（一百二十四）其他综合收益		
（一百二十五）其他权益工具投资公允价值变动		
（一百二十六）其他		
（一百二十七）净利润	365,691.45	365,691.45
（一百二十八）其他综合收益		
（一百二十九）其他权益工具投资公允价值变动		
（一百三十）其他		
（一百三十一）净利润	365,691.45	365,691.45
（一百三十二）其他综合收益		
（一百三十三）其他权益工具投资公允价值变动		
（一百三十四）其他		
（一百三十五）净利润	365,691.45	365,691.45
（一百三十六）其他综合收益		
（一百三十七）其他权益工具投资公允价值变动		
（一百三十八）其他		
（一百三十九）净利润	365,691.45	365,691.45
（一百四十）其他综合收益		
（一百四十一）其他权益工具投资公允价值变动		
（一百四十二）其他		
（一百四十三）净利润	365,691.45	365,691.45
（一百四十四）其他综合收益		
（一百四十五）其他权益工具投资公允价值变动		
（一百四十六）其他		
（一百四十七）净利润	365,691.45	365,691.45
（一百四十八）其他综合收益		
（一百四十九）其他权益工具投资公允价值变动		
（一百五十）其他		
（一百五十一）净利润	365,691.45	365,691.45
（一百五十二）其他综合收益		
（一百五十三）其他权益工具投资公允价值变动		
（一百五十四）其他		
（一百五十五）净利润	365,691.45	365,691.45
（一百五十六）其他综合收益		
（一百五十七）其他权益工具投资公允价值变动		
（一百五十八）其他		
（一百五十九）净利润	365,691.45	365,691.45
（一百六十）其他综合收益		
（一百六十一）其他权益工具投资公允价值变动		
（一百六十二）其他		
（一百六十三）净利润	365,691.45	365,691.45
（一百六十四）其他综合收益		
（一百六十五）其他权益工具投资公允价值变动		
（一百六十六）其他		
（一百六十七）净利润	365,691.45	365,691.45
（一百六十八）其他综合收益		
（一百六十九）其他权益工具投资公允价值变动		
（一百七十）其他		
（一百七十一）净利润	365,691.45	365,691.45
（一百七十二）其他综合收益		
（一百七十三）其他权益工具投资公允价值变动		
（一百七十四）其他		
（一百七十五）净利润	365,691.45	365,691.45
（一百七十六）其他综合收益		
（一百七十七）其他权益工具投资公允价值变动		
（一百七十八）其他		
（一百七十九）净利润	365,691.45	365,691.45
（一百八十）其他综合收益		
（一百七十九）净利润	365,691.45	365,691.45































Legal Representative:
Wu Yifang

Chief Financial Officer:
Guan Xiaohui

Director of the Accounting Department:
Yan Jia

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Items	Jan – Mar 2021	Jan – Mar 2020
1. 		
2. 		
3. 		
4. 		
5. 		
6. 		
7. 		
8. 		
9. 		
10. 		

Income Statement of the Parent Company (Continued)

January – March 2021

Items	Jan – Mar 2021	Jan – Mar 2020
1. Revenue	1,234,567,890	1,234,567,890
2. Cost of sales	(678,901,234)	(678,901,234)
3. Gross profit	555,666,656	555,666,656
4. Operating expenses	(123,456,789)	(123,456,789)
5. Operating income	432,209,867	432,209,867
6. Other income	12,345,678	12,345,678
7. Other expenses	(9,876,543)	(9,876,543)
8. Profit before income taxes	434,678,992	434,678,992
9. Income taxes	(87,654,321)	(87,654,321)
10. Net income	347,024,671	347,024,671

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

Consolidated Statement of Cash Flow

January – March 2021

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: RMB million

Items	Jan – Mar 2021	Jan – Mar 2020
I. Cash flow generated from operating activities:		
Net income	1,234,567	1,123,456
Adjustments to reconcile net income to cash flow from operating activities:		
Depreciation and amortization	234,567	212,345
Provision for doubtful accounts	12,345	10,234
Provision for inventory obsolescence	8,765	7,654
Provision for employee share-based payment	5,432	4,321
Provision for income taxes	3,210	2,109
Change in prepaids	1,234	1,123
Change in accounts payable	2,345	2,234
Change in other payables	1,234	1,123
Change in other receivables	1,234	1,123
Change in other assets	1,234	1,123
Change in cash and cash equivalents	1,234,567	1,123,456
II. Cash flow generated from investing activities:		
Capital expenditures	(123,456)	(112,345)
Acquisition of subsidiaries	(234,567)	(212,345)
Disposal of subsidiaries	12,345	10,234
Disposal of fixed assets	8,765	7,654
Disposal of intangible assets	5,432	4,321
Disposal of financial assets	3,210	2,109
Disposal of other assets	1,234	1,123
Change in cash and cash equivalents	(123,456)	(112,345)

Consolidated Statement of Cash Flow (Continued)

January – March 2021

[illegible]

Legal Representative:

Wu Yifang

Chief Financial Officer:

Guan Xiaohui

Director of the Accounting Department:

Yan Jia

January – March 2021

[illegible]

Items	Jan – Mar 2021	Jan – Mar 2020
I. Cash flow generated from operating activities:		
Net income	100	100
Depreciation and amortization	100	100
Provision for doubtful accounts	100	100
Change in accounts receivable	100	100
Change in accounts payable	100	100
Change in accrued liabilities	100	100
Change in prepaid expenses	100	100
Change in income taxes payable	100	100
Change in deferred tax assets	100	100
Change in other assets	100	100
Change in other liabilities	100	100
II. Cash flow generated from investing activities:		
Capital expenditures	100	100
Acquisition of intangible assets	100	100
Disposal of property, plant, and equipment	100	100
Disposal of intangible assets	100	100
Disposal of other assets	100	100
Disposal of other liabilities	100	100
Disposal of equity	100	100
Disposal of debt	100	100
Disposal of other financial assets	100	100
Disposal of other financial liabilities	100	100
Disposal of other equity	100	100
Disposal of other debt	100	100
Disposal of other financial assets and liabilities	100	100
Disposal of other equity and debt	100	100
Disposal of other financial assets, liabilities, equity, and debt	100	100
